Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1

Recruiting

Conditions: Biliary Tract Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Ovarian Neoplasms
Endometrial Neoplasms
Pancreatic Neoplasms

Interventions: Drug: LY3537982
Drug: Pembrolizumab
Drug: Cetuximab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-07-09

Last Posted Date: 2024-10-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 550

Registration Number: NCT04956640

Locations: 🇫🇷
Centre Leon Berard, Lyon, Rhône-Alpes, France
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇦🇺
Peninsula and Southeast Oncology, Frankston, Victoria, Australia

and more 46 locations

A Study of LY3532226 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3532226
Drug: Placebo

First Posted Date: 2021-06-11

Last Posted Date: 2021-12-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT04923269

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of LY3819469 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3819469

First Posted Date: 2021-06-04

Last Posted Date: 2022-11-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT04914546

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Qps-Mra, Llc, Miami, Florida, United States

and more 2 locations

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lasmiditan

First Posted Date: 2021-05-11

Last Posted Date: 2023-03-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 47

Registration Number: NCT04881747

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Phase 2

Completed

Conditions: Obesity
Overweight

Interventions: Drug: LY3437943
Drug: Placebo

First Posted Date: 2021-05-11

Last Posted Date: 2023-09-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 338

Registration Number: NCT04881760

Locations: 🇺🇸
Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States
🇺🇸
Juno Research, Houston, Texas, United States
🇺🇸
Perseverance Research Center, Scottsdale, Arizona, United States

and more 24 locations

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

Phase 2

Completed

Conditions: Chronic Low-back Pain

Interventions: Drug: LY3556050
Drug: Placebo

First Posted Date: 2021-05-06

Last Posted Date: 2023-11-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT04874636

Locations: 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸
Synexus- Chandler, Chandler, Arizona, United States
🇺🇸
Synexus Clinical Research US, Inc - Orlando, The Villages, Florida, United States

and more 30 locations

A Study of LY3437943 in Participants With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: LY3437943
Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2021-04-30

Last Posted Date: 2023-07-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 281

Registration Number: NCT04867785

Locations: 🇺🇸
Humphreys Diabetes Center, Boise, Idaho, United States
🇺🇸
Logan Health Research, Kalispell, Montana, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States

and more 37 locations

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

Phase 4

Withdrawn

Conditions: Type 2 Diabetes Treated With Insulin
Type 2 Diabetes

Interventions: Drug: Basal Insulin

First Posted Date: 2021-04-29

Last Posted Date: 2021-08-24

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT04864977

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Phase 3

Completed

Conditions: Obesity
Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2021-04-19

Last Posted Date: 2024-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 731

Registration Number: NCT04847557

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Northwest Houston Heart Center, Tomball, Texas, United States
🇺🇸
Excel Medical Clinical Trials, Boca Raton, Florida, United States

and more 140 locations

A Device Study in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Device: On-Body Delivery System (OBDS)/Multiple Bolus Injector
Device: Single Auto Injector
Drug: Placebo

First Posted Date: 2021-04-19

Last Posted Date: 2023-03-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT04848402

Locations: 🇬🇧
LABCORP, Leeds, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy